Chemokines are a family of proinflammatory cytokines that attract and activate specific types of leukocytes. Chemokines mediate their effects via interaction with seven transmembrane G protein–coupled receptors (GPCR). Using CCR5-transfected HEK-293 cells, we show that both the CCR5 ligand, RANTES, as well as its derivative, aminooxypentane (AOP)- RANTES, trigger immediate responses such as Ca2+ influx, receptor dimerization, tyrosine phosphorylation, and Gαi as well as JAK/STAT association to the receptor. In contrast to RANTES, (AOP)-RANTES is unable to trigger late responses, as measured by the association of focal adhesion kinase (FAK) to the chemokine receptor complex, impaired cell polarization required for migration, or chemotaxis. The results are discussed in the context of the dissociation of the late signals, provoked by the chemokines required for cell migration, from early signals.
Skip Nav Destination
Article navigation
22 February 1999
Article|
February 22 1999
Similarities and Differences in RANTES- and (AOP)-RANTES–triggered Signals: Implications for Chemotaxis
José M. Rodríguez-Frade,
José M. Rodríguez-Frade
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Search for other works by this author on:
Antonio J. Vila-Coro,
Antonio J. Vila-Coro
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Search for other works by this author on:
Ana Martín,
Ana Martín
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Search for other works by this author on:
Marta Nieto,
Marta Nieto
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Search for other works by this author on:
Francisco Sánchez-Madrid,
Francisco Sánchez-Madrid
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Search for other works by this author on:
Amanda E.I. Proudfoot,
Amanda E.I. Proudfoot
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Search for other works by this author on:
Timothy N.C. Wells,
Timothy N.C. Wells
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Search for other works by this author on:
Carlos Martínez-A,
Carlos Martínez-A
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Search for other works by this author on:
Mario Mellado
Mario Mellado
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Search for other works by this author on:
José M. Rodríguez-Frade
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Antonio J. Vila-Coro
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Ana Martín
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Marta Nieto
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Francisco Sánchez-Madrid
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Amanda E.I. Proudfoot
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Timothy N.C. Wells
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Carlos Martínez-A
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Mario Mellado
*Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain; ‡Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Diego de León 62, E-28006 Madrid, Spain; and §Serono Pharmaceutical Research Institute, Plan-les-Ouates, Geneva CH-1228, Switzerland
Address correspondence to Carlos Martínez-A., Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049 Madrid, Spain. Tel.: 34-91-585-4559. Fax: 34-91-372-0493. E-mail: [email protected]
Received:
August 25 1998
Revision Received:
December 18 1998
Online ISSN: 1540-8140
Print ISSN: 0021-9525
1999
J Cell Biol (1999) 144 (4): 755–765.
Article history
Received:
August 25 1998
Revision Received:
December 18 1998
Citation
José M. Rodríguez-Frade, Antonio J. Vila-Coro, Ana Martín, Marta Nieto, Francisco Sánchez-Madrid, Amanda E.I. Proudfoot, Timothy N.C. Wells, Carlos Martínez-A, Mario Mellado; Similarities and Differences in RANTES- and (AOP)-RANTES–triggered Signals: Implications for Chemotaxis . J Cell Biol 22 February 1999; 144 (4): 755–765. doi: https://doi.org/10.1083/jcb.144.4.755
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement
Advertisement